Skip to main content

Table 1 Patient and donor characteristics in the retrospective study

From: Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

Characteristics All patients MSDT   HBMT  
MRDneg MRDpos MRDneg MRDpos
Number of patients 339 85 14   189 51  
Median age (range), years 31 (2–60) 41 (12–57) 44 (5–57) 0.457 27 (2–60) 28 (9–57) 0.151
Weight (range), kg 61 (15.5–118) 66.5 (29–97) 68 (23–96) 1.000 64 (15.5–118) 60 (25–102) 0.286
Male, n (%) 165 (48.7%) 41 (48.2%) 9 (64.3%) 0.263 96 (50.8%) 19 (37.3%) 0.086
Diagnosis, n (%)     0.264    0.031
 De novo AML 333 (98.2%) 84 (98.8%) 13 (92.9%)   188 (99.5%) 48 (94.1%)  
 Secondary AML 6 (1.8%) 1 (1.2%) 1 (7.1%)   1 (0.5%) 3 (5.9%)  
Disease status, n (%)     0.217    0.137
 CR1 301 (88.8%) 81 (95.3%) 12 (85.7%)   167 (88.4%) 41 (80.4%)  
 CR > 1 38 (11.2%) 4 (4.7%) 1 (14.3%)   22 (11.6%) 10 (19.6%)  
FLT3-ITD mutation     0.302    0.582
 Yes 20 (5.9%) 5 (5.9%) 2 (14.3%)   11 (5.8%) 2 (3.9%)  
 No 319 (94.1%) 80 (94.1%) 12 (85.7%)   178 (94.2%) 49 (96.1%)  
Cytogenetics     0.247    0.285
 Favorable 59 (17.4%) 16 (18.8%) 1 (7.1%)   30 (15.9%) 12 (23.5%)  
 Intermediate 263 (77.6%) 65 (76.5%) 13 (92.9%)   150 (79.4%) 35 (68.6%)  
 Adverse 17 (5.0%) 4 (4.7%) 0   9 (4.8%) 4 (7.8%)  
Conditioning regimen, n (%)
 MA 339 (100%) 85 (100%) 14 (100%)   189 (100%) 51 (100%)  
HLA-A-, B-, and DR-mismatched grafts, n (%)        0.245
 0 101 (29.8%) 85 (100%) 14 (100%)   1 (0.5%) 1 (2.0%)  
 1 14 (4.1%) 0 0   13 (6.9%) 1 (2.0%)  
 2 55 (16.2%) 0 0   40 (21.2%) 15 (29.4%)  
 3 126 (49.9%) 0 0   135 (71.4%) 34 (66.7%)  
Donor-recipient sex-matched grafts, n (%)     0.249    0.481
 Male–male 104 (30.7%) 22 (25.9%) 4 (28.6%)   62 (32.8%) 16 (31.4%)  
 Male–female 86 (25.3%) 25 (29.4%) 1 (7.1%)   55 (29.1%) 14 (27.5%)  
 Female–male 95 (28.0%) 32 (37.6%) 8 (57.1%)   44 (23.3%) 8 (17.6%)  
 Female–female 47 (13.9%) 6 (7.1%) 1 (7.1%)   28 (14.8%) 12 (23.5%)  
Donor-recipient relationship, n (%)        0.439
 Parent–child 128 (37.8%) 0 0   104 (55.0%) 24 (47.1%)  
 Sibling–sibling 176 (51.9%) 85 (100%) 14 (100%)   58 (30.7%) 19 (37.3%)  
 Child–parent 32 (9.4%) 0 0   24 (12.7%) 8 (15.7%)  
 Other 3 (0.9%) 0 0   3 (1.6%) 0 (0%)  
ABO matched grafts, n (%)        0.087
 Matched 201 (59.3%) 53 (62.4%) 9 (64.3%) 0.345 104 (55.0%) 35 (68.6%)  
 Major mismatch 62 (18.3%) 19 (22.4%) 1 (7.1%)   39 (20.6%) 3 (5.9%)  
 Minor mismatch 58 (17.1%) 9 (10.6%) 2 (14.3%)   36 (19.0%) 11 (21.6%)  
 Bi-directional mismatch 18 (5.3%) 4 (4.7%) 2 (14.3%)   10 (5.3%) 2 (3.9%)  
EBMT score, n (%)     0.063    0.850
 0 0 0 0   0 0  
 1 73 (21.5%) 23 (27.1%) 3 (21.4%)   38 (20.1%) 9 (17.6%)  
 2 156 (46.0%) 50 (58.8%) 7 (50.0%)   78 (41.3%) 21 (41.2%)  
 3 76 (22.4%) 11 (12.9%) 1 (7.1%)   50 (26.5%) 14 (27.5%)  
 4 25 (7.4%) 1 (1.2%) 2 (14.2%)   18 (9.5%) 4 (7.8%)  
 5 9 (2.7%) 0 1 (7.1%)   5 (2.6%) 3 (5.9%)  
Cell compositions in allografts
 Infused nuclear cells, (range) 108/kg 7.51 (3.98–16.77) 7.51 (3.98–14.75)(5.18–14.93) 7.12 (5.78–12.75) 0.896 7.40 (4.32–16.77) 7.69 (5.4–14.07) 0.262
 Infused CD34+ cells, (range) 106/kg 2.32 (0.50–9.78) 2.26 (0.76–9.78) 2.05 (1.16–5.04) 0.670 2.32 (0.50–9.47) 2.46 (1.04–8.80) 0.448
DLI after transplant, n (%)
 For relapse prophylaxis and intervention 28 (8.3%) 6 (7.1%) 4 (28.6%) 0.046 13 (6.9%) 5 (9.8%) 0.686
 For relapse treatment 19 (5.6%) 2 (2.4%) 2 (14.3%) 0.171 12 (6.3%) 3 (5.9%) 0.902
  1. Abbreviations: HLA human leukocyte antigen, MSDT HLA-matched sibling donor transplantation, HBMT unmanipulated haploidentical blood and marrow transplantation, MRD minimal residual disease, neg negative, pos positive, AML acute myeloid leukemia, CR complete remission, MA myeloablative regimen, EBMT European Group for Blood and Marrow Transplantation, DLI donor lymphocyte infusions